Donate
With your essential support,
GARDP can advance solutions for antibiotic resistance. Thank you.
We develop treatments for any person who needs them, wherever they live.
Those who suffer most include children and newborns, people with weakened immune systems, and the elderly, especially in low- and middle-income countries.
Those who suffer most include children and newborns, people with weakened immune systems, and the elderly, especially in low- and middle-income countries.
Stopping the spread of antibiotic resistance contributes to the health and safety of people everywhere.
“The right antibiotic at the right dose and the right time can mean the difference between life and death for a patient with a serious bacterial infection. We need not only to replenish the antibiotic R&D pipeline, but also to ramp up efforts to expand access to antibiotics, particularly in low- and middle-income countries, to counter the growing threat of antibiotic resistance.”
– Manica Balasegaram, Executive Director, GARDP
GARDP Strategy 2024-2028
GARDP Strategy 2024-2028
Our strategy is designed to enable the development and availability of the right antibiotic treatments for those who need them. By focusing on both immediate and long-term solutions to AMR, we aim to create a new global antibiotic pipeline, an ecosystem for antibiotic R&D and access, that is driven by public health need.